Quick Answer
Inhibitor Therapeutics, Inc. reported Net Income Loss of -$3.30 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +1.2% in Net Income Loss from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Inhibitor Therapeutics, Inc.'s Net Income Loss has declined by 1,870.9%.
- Historical annual values: Fiscal year 2025: -$3.30 million | Fiscal year 2024: -$3.34 million | Fiscal year 2023: -$3.03 million | Fiscal year 2022: $12.11 million | Fiscal year 2021: -$298.6 thousand | Fiscal year 2020: -$1.06 million | Fiscal year 2019: -$2.73 million | Fiscal year 2018: -$4.55 million | Fiscal year 2017: -$5.10 million | Fiscal year 2016: -$7.00 million | Fiscal year 2015: -$3.95 million | Fiscal year 2014: -$3.98 million | Fiscal year 2013: -$1.84 million | Fiscal year 2012: $186.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: